Alan Ashworth
Co-discovered that BRCA-deficient cancers die when PARP is blocked, the idea behind an entire drug class.
Molecular biologist who co-identified BRCA2 and, with colleagues at the Institute of Cancer Research, showed the synthetic lethality of PARP inhibition in BRCA-deficient cells. Leads UCSF's cancer centre.
| Title | Journal | Year |
|---|---|---|
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Nature | 2005 |
| Synthetic lethal therapies for cancer: what's next after PARP inhibitors? | Nature Reviews Clinical Oncology | 2018 |
Pages like this
not linked directly; found by shared links- TrialSOLO-1
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- TrialPOLO
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonChristopher Lord
Shares Synthetic lethality approaches, PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD).
- PersonJennifer K. Litton
Shares PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- InstitutionNewcastle Cancer Centre / Northern Centre for Cancer Care
Shares Synthetic lethality approaches, PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD).
- ProductIniparib
Shares PARP inhibitors, Olaparib, PARP, Triple-negative breast cancer (TNBC).